Browse > Article

A Case of Malignant Melanoma During Hormone Therapy  

Sung, Jung-Yeob (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University)
Kim, Hoon (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University)
Kim, Yong-Jin (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University)
Ku, Seung-Yup (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University)
Kim, Seok-Hyun (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University)
Choi, Young-Min (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University)
Kim, Jung-Gu (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University)
Moon, Shin-Yong (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University)
Publication Information
Clinical and Experimental Reproductive Medicine / v.36, no.3, 2009 , pp. 225-230 More about this Journal
Abstract
Over the last several decades, the incidence of malignant melanoma has been increasing rapidly. The annual incidence rates have increased approximately 3~7% in Caucasian population. The rate of increase is highest in perimenopausal period in women. The relationship between risk of melanoma and female hormone is still unclear. The safety of hormone therapy for the melanoma patients is not known. We experienced a case of melanoma in whom underwent hormone therapy for 10 years. We report this case with a brief review of literature.
Keywords
Malignant melanoma; Hormone therapy; Estrogen; Menopause;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Marks R. Epidemiology of melanoma. Clin Exp Dermatol 2000; 25: 459-63   DOI   PUBMED   ScienceOn
2 Osterlind A, Tucker MA, Stone BJ, Jensen OM. The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women. Int J Cancer 1988; 42: 821-4   DOI   PUBMED
3 Feskanich D, Hunter DJ, Willett WC, Spiegelman D, Stampfer MJ, Speizer FE, et al. Oral contraceptive use and risk of melanoma in premenopausal women. Br J Cancer 1999; 81: 918-23   DOI   ScienceOn
4 Palmer HR, Rosenberg L, Strom BL, Harlap S, Zauber AG, Warchauer ME, et al. Oral contraceptive use and risk of cutaneous malignant melanoma. Cancer Causes Control 1992; 3: 547-54   DOI   ScienceOn
5 Sanchez NP, Pathak M, Sato S, Fitzpatrick TB, Sanchez JL, Mihm Mc jr. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol 1981; 4: 698-710   DOI   ScienceOn
6 Karagas MR, Stukel TA, Dykes J, Miglionico J, Greene MA, Carey M, et al. A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use. Br J Cancer 2002; 86: 1085-92   DOI   ScienceOn
7 Chaudhuri PK, Walker MJ, Briele HA, Beattie CW, Gupta TK. Incidence of estrogen receptors in benign nevi and human malignant melanoma. JAMA 1980; 244: 791-3   DOI   ScienceOn
8 Durvasula R, Ahmed SM, Vashisht A, Studd JW. Hormone replacement therapy and malignant melanoma: to prescribe or not to prescribe? Climacteric 2002; 5: 197-200   PUBMED   ScienceOn
9 Nicholas K. Genetics of melanoma predisposition. Oncogene 2003; 22: 3053-62   DOI   PUBMED   ScienceOn
10 Lea CS, Holly EA, Hartge P, Lee JS, Guerry D 4th, Elder DE, et al. Reproductive risk factors for cutaneous melanoma in women: a case-control study. Am J Epidemiol 2007; 165: 505-13   PUBMED   ScienceOn
11 Kalogirou D, Aroni K, Kalogirou O, Antoniou G, Botsis D, Kontoravdis A. Histological changes induced by tibolone and estrogen/glucocorticoid on aging skin. Int J Fertil Womens Med. 2000; 45: 273-8   PUBMED
12 Snell RS, Bischitz PG. The effect of large doses of estrogen and progesterone on melanin pigmentation. J invest Dermatol 1960; 35: 73-82   PUBMED   ScienceOn
13 Mackie RM, Bray CA. Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma. Br J cancer 2004; 90: 770-2   DOI   ScienceOn
14 Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. A cancer journal for clinicians 2008; 58: 71-96   DOI   ScienceOn
15 Bressac-de-Paillerets B, Avril MF, Chompret A, Demenais F. Genetic and environmental factors in cutaneous malignant melanoma. Biochimie 2002; 84: 67-74   DOI   ScienceOn
16 Miller JG, Gee J, Price A, Garbe C, Wagner M, Mac Neil S. Investigation of oestrogen receptors, sex steroids and soluble adhesion molecules in the progression of malignant melanoma. Melanoma Res 1997; 7: 197-208   DOI   ScienceOn
17 Fisher RI, Neifeld JP, Lippman ME. Oestrogen receptors in human malignant melanoma. Lancet 1976; 2: 337-9   PUBMED
18 Boyle P, Robertson C. Age-period-cohort modeling of malignant melanoma in Scotland : epidemiologic implications. Am J Epidemiol 1987; 125: 766
19 Bertrand G. Melanotic adenocarcinoma of the uterus. Neuroendocrine tumor of the uterus. Ann pathol 1988; 9: 295-304   DOI   ScienceOn